

1 **Title:** White blood cells and severe COVID-19: a Mendelian randomization study

2

3 Yitang Sun¹, Jingqi Zhou^{1,2}, Kaixiong Ye^{1,3,*}

4

5 ¹ Department of Genetics, Franklin College of Arts and Sciences, University of Georgia,
6 Athens, GA, USA

7 ² School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai,
8 P.R. China

9 ³ Institute of Bioinformatics, University of Georgia, Athens, GA, USA

10

11 *** Address for Correspondence:**

12

13 Dr. Kaixiong Ye

14 Department of Genetics

15 University of Georgia

16 C220 Davison Life Sciences

17 120 East Green Street, Athens, GA 30602

18 Office: 706-542-5898

19 Fax: 706-542-3910

20 Email:

Kaixiong.Ye@uga.edu

21 **Abstract**

22

23 **Background:** The pandemic of coronavirus disease 2019 (COVID-19), caused by
24 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly emerged
25 to seriously threaten public health. We aimed to investigate whether white blood cell
26 traits have potential causal effects on severe COVID-19 using Mendelian randomization
27 (MR).

28

29 **Methods:** To evaluate the causal associations between various white blood cell traits
30 and severe COVID-19, we conducted a two-sample MR analysis with summary
31 statistics from recent large genome-wide association studies.

32

33 **Results:** Our MR results indicated potential causal associations of white blood cell
34 count, myeloid white blood cell count, and granulocyte count with severe COVID-19,
35 with odds ratios (OR) of 0.84 (95% CI: 0.72-0.98), 0.81 (95% CI: 0.70-0.94), and 0.84
36 (95% CI: 0.71-0.99), respectively. Increasing eosinophil percentage of white blood
37 cells was associated with a higher risk of severe COVID-19 (OR: 1.22, 95% CI: 1.03-
38 1.45).

39

40 **Conclusions:** Our results suggest the potential causal effects of lower white blood cell
41 count, lower myeloid white blood cell count, lower granulocyte count, and higher
42 eosinophil percentage of white blood cells on an increased risk of severe COVID-19.

43

44 **Key Words:** COVID-19; white blood cells; eosinophil; Mendelian randomization

45

46 **Background**

47 Coronavirus disease 2019 (COVID-19) is caused by infection of a novel virus called
48 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1]. SARS-CoV-2
49 has rapidly spread, causing damage or even death [2-4]. Besides age and gender,
50 some pre-existing conditions are also well-known to be associated with an increased
51 risk of severe COVID-19, such as cardiovascular disease, diabetes, chronic respiratory
52 disease, hypertension, and cancers [4-7]. Recently, genetic studies, including two
53 genome-wide association studies (GWAS), have identified multiple genetic loci to be
54 associated with the susceptibility and severity of COVID-19 [8-10]. However, causal risk
55 factors for severe COVID-19 remain unclear. Identifying host factors predisposing
56 individuals to severe COVID-19 is urgently needed to improve primary prevention and to
57 develop treatment strategies.

58

59 Elevated white blood cell and neutrophil counts, and depleted lymphocyte count have
60 been repeatedly observed in COVID-19 patients with severe outcomes, and neutrophil-
61 to-lymphocyte ratio have been proposed as a prognostic biomarker [1, 11-14]. However,
62 findings from recent observational studies are inconsistent and the exact roles of white
63 blood cells and its various subtypes in severe COVID-19 remain elusive [15-17]. Most
64 existing studies measured blood cell counts in patients with confirmed infection of
65 SARS-CoV-2 and as a result, the hematological indices could have been modified by
66 immune responses [18]. It is unknown if blood cell counts before infection are

67 associated with the risk of developing severe COVID-19. Even if white blood cells are
68 measured before infection, they are influenced by many exogenous and endogenous
69 factors (e.g., age, gender, disease status, and medications), which will confound the
70 observational associations [19, 20]. No previous research has been able to interrogate
71 the causal role of white blood cells in severe COVID-19.

72
73 While traditional observational associations often suffer from confounding, reverse
74 causality, and various biases, a complementary approach, Mendelian randomization
75 (MR), utilizes genetic variants as instrumental variables to approximate the lifetime
76 status of exposure and enable causal inference in observational data. The random
77 allocation of the allele at conception and the natural directional effects of genetic
78 variants empower MR estimates to be less plagued by confounding and reverse
79 causality [21, 22]. In this study, we aimed to test the causal effects of 19 white blood cell
80 traits on severe COVID-19 by performing a two-sample MR analysis.

81 **Methods**

82 **Study design and data source**

83 A two-sample MR study was conducted to examine the causal effects of 19 white blood
84 cell traits on severe COVID-19. These blood cell traits were chosen based on a GWAS
85 meta-analysis in 173,480 European ancestry individuals across three cohorts, and their
86 summary statistics were available in the IEU OpenGWAS database [23, 24]. Genetic
87 instruments for each white blood cell trait were chosen based on the following criteria: 1)
88 $p < 8.31 \times 10^{-9}$ for association with the exposure; and 2) linkage disequilibrium (LD)
89 clumping based on $r^2 > 0.001$. The data source and details for 19 white blood cell traits
90 are available in Supplementary Table 1. The instrument-outcome effects were retrieved
91 from the largest GWAS meta-analysis of COVID-19 to date, by the COVID-19 Host
92 Genetics Initiative (HGI, release 3, accessed on July 2, 2020) [10]. We used the
93 summary statistics based on the comparison of hospitalized COVID-19 patients (N =
94 3,199) with the general population (N = 897,488).

95

96 **Statistical analysis**

97 The causal effect of a white blood cell trait on severe COVID-19 was evaluated using
98 the inverse variance-weighted (IVW) method with a multiplicative random-effects model
99 [22, 25, 26]. Horizontal pleiotropy occurs when SNPs exert a direct effect on the severe
100 COVID-19 through pathways other than the hypothesized exposure. To evaluate the
101 possible presence of horizontal pleiotropy, we calculated Cochran's Q statistic for
102 heterogeneity and conducted the intercept test associated with the MR-Egger method.
103 Additional sensitivity analyses were performed with MR-Egger [22, 26], weighted

104 median (WM) [27], and Mendelian randomization pleiotropy residual sum and outlier
105 (MR-PRESSO) test [28]. The MR-Egger estimates allowed directional or unbalanced
106 horizontal pleiotropic effects. The weighted median method provides robust causal
107 estimates even when up to 50 % SNPs are invalid genetic instruments [27]. The MR-
108 PRESSO test was utilized to correct for the presence of specific horizontal pleiotropic
109 outlier variants via detected outlier removal [28]. All MR analyses were conducted in R
110 with the TwoSampleMR package [23].

111

112 **Resources**

113 The COVID-19 Host Genetics Initiative: <https://www.covid19hg.org/>

114 The IEU OpenGWAS database: <https://gwas.mrcieu.ac.uk/>

115 **Results**

116 **The counts of white blood cell, myeloid white blood cell, and granulocyte are** 117 **negatively associated with severe COVID-19**

118 By applying a two-sample MR approach, we first investigated the causal associations of
119 the counts of white blood cell and its subpopulations with severe COVID-19. A relatively
120 large number of independent SNPs, ranging from 79 for basophil count to 185 for
121 monocyte count, were selected as genetic instruments for each blood cell count
122 (Supplementary Tables 2-11). Based on the IVW MR estimates under a multiplicative
123 random-effects model, we identified potentially causal, negative associations of white
124 blood cell count (OR = 0.84, CI: 0.72-0.98, $p = 0.031$), basophil count (OR = 0.75, CI:
125 0.58-0.96, $p = 0.023$), myeloid white blood cell count (OR = 0.81, CI: 0.70-0.94, $p =$
126 0.0070), and granulocyte count (OR = 0.84, CI: 0.71-0.99, $p = 0.040$) with severe
127 COVID-19 (Fig. 1, Table 1). A suggestive negative association was also found for sum
128 neutrophil eosinophil counts (OR = 0.85, CI: 0.73-1.00, $p = 0.051$). No evidence of
129 heterogeneity in causal estimates was found by the Cochran Q statistic, and no
130 evidence of horizontal pleiotropy was reported by the MR-Egger intercept test, except
131 for basophil count ($p = 0.036$). Causal estimates from MR-Egger and WM MR revealed
132 broadly concordant effect directions, although they are mostly not statistically significant,
133 probably due to the reduced power of these two approaches [26] (Supplementary Fig. 1,
134 Supplementary Table 21). MR-PRESSO analysis did not identify any outlier SNPs and
135 yielded significant causal estimates for white blood cell count ($p = 0.033$), myeloid white
136 blood cell count ($p = 0.0078$), and granulocyte count ($p = 0.041$) (Supplementary Table
137 21). Taken together, we demonstrated that white blood cell count, myeloid white blood

138 cell count, and granulocyte count had consistent, negative effects on the risk of severe
139 COVID-19.

140

141 **The percentage of eosinophil in white blood cell is positively associated with**
142 **severe COVID-19**

143 We further investigated the causal associations of the percentages of specific white
144 blood cells with severe COVID-19. As genetic instruments, we used 158 SNPs for
145 eosinophil percentage, 63 SNPs for basophil percentage, 135 SNPs for the neutrophil
146 percentage, 191 SNPs for monocyte percentage, and 135 SNPs for lymphocyte
147 percentage (Supplementary Tables 12-16).

148

149 Genetically predicted higher eosinophil percentage of white blood cells (OR = 1.22, CI:
150 1.03-1.45, $p = 0.023$) was associated with increased risk of severe COVID-19 using
151 IVW with the random-effect model (Figure 1). The WM MR method and the MR-
152 PRESSO analysis both revealed a consistent, positive effect (OR = 1.41, CI: 1.07-1.87,
153 $p = 0.015$; and OR = 1.22, CI: 1.03-1.45, $p = 0.024$; respectively. Supplementary Table
154 21). No pleiotropy or outlier SNPs were identified in the MR-Egger test and MR-
155 PRESSO analysis. Cochran Q statistics indicated no heterogeneity among the genetic
156 instruments (Supplementary Table 21).

157

158 **The percentage of eosinophil in granulocyte is positively associated with severe**
159 **COVID-19**

160 We further focused on the granulocyte and evaluated if it specific compositions are
161 associated with severe COVID-19. As genetic instruments, there were 168 SNPs for
162 granulocyte percentage of myeloid white blood cells, 150 SNPs for eosinophil
163 percentage of granulocytes, 59 SNPs for basophil percentage of granulocytes, and 141
164 SNPs for the neutrophil percentage of granulocytes (Supplementary Tables 17-20). Our
165 results found suggestive evidence for a risk-increasing effect of eosinophil percentage
166 of granulocytes on severe COVID-19 (OR = 1.18, CI: 1.00-1.39, $p = 0.053$). The WM
167 MR method and the MR-PRESSO analysis both revealed a consistent positive effect
168 (OR = 1.35, CI: 1.03-1.75, $p = 0.029$; and OR = 1.18, CI: 1.00-1.39, $p = 0.055$;
169 respectively). No evidence of heterogeneity and pleiotropy was found. No statistically
170 significant causal associations were identified for other specific granulocyte percentages
171 (Figure 1 and Supplementary Table 21).

172 **Discussion**

173 To our knowledge, this is the first MR study evaluating the causal roles of white blood
174 cell traits in severe COVID-19 risk. Overall, our results suggest potential causal
175 protective effects of increasing white blood cell count, myeloid white blood cell count,
176 and granulocyte count on severe COVID-19. Our novel findings also include that
177 genetically predicted higher eosinophil percentage in white blood cells or in
178 granulocytes was associated with a higher risk of severe COVID-19.

179
180 Previous observational studies have frequently pointed out increased white blood cell
181 count in the severe COVID-19 patients, when compared to healthy controls or mild
182 COVID-19 patients [1, 11, 12, 29]. However, there are also reports that normal or
183 decreased white blood cell count is more common in COVID-19 patients when
184 compared to the reference range or healthy controls [10, 15-17, 30-32]. Our MR analysis
185 showed that lower white blood cell count, myeloid white blood cell count, and
186 granulocyte count may play a causal role in increasing the risk of severe COVID-19.
187 The mechanism by which they contribute to severe COVID-19 remains unclear. Immune
188 system disorders have been suspected of playing roles in severe COVID-19 risk [33,
189 34]. The complete elucidation of the potential mechanism warrants further investigation.

190
191 Persistent eosinopenia after admission was associated with COVID-19 risk in previous
192 retrospective and prospective observational studies [12, 15, 31, 32, 35-37]. There are
193 also reports that eosinophil remains stable in severe COVID-19 patients [13, 29, 38, 39].
194 A multiparametric flow cytometry analysis found that high eosinophil count was

195 associated with an increased risk of severe COVID-19 [13]. Another observational study
196 suggested that increasing eosinophil count might be an indicator of COVID-19
197 improvement [40]. Our MR analysis supported that high eosinophil percentage of white
198 blood cells may be causal in increasing the risk of severe COVID-19 [40, 41], calling for
199 future mechanistic studies.

200
201 Lymphopenia, as a response to viral infection, has been frequently associated with
202 severe COVID-19 risk [1, 2, 13, 29, 41-51]. However, we did not detect a causal effect
203 of lymphocyte count on severe COVID-19. This discrepancy may reflect reverse
204 causality in retrospective and prospective observational studies, with depleted
205 lymphocyte count as a result of immune response to SARS-CoV-2 infection [52]. Due
206 to the limited number of SNPs associated with severe COVID-19, performing reverse
207 MR analyses between severe COVID-19 and white blood cell traits is challenging. Using
208 linkage disequilibrium (LD) assessment, only one SNP at locus 3p21.31 was retained in
209 the previously published genome-wide significant SNPs [10]. We recently showed that
210 SNPs at this locus are associated with multiple blood cell traits, suggesting they may
211 have pleiotropic effects and are not suitable to be used as genetic instruments [53]. As
212 more COVID-19-associated SNPs are identified in the future, reverse MR analysis will
213 be valuable to understand the effect of COVID-19 on blood cell traits.

214
215 One assumption of MR is that the instrumental variable influences severe COVID-19
216 risk only through its effect on a specific white blood cell trait. The Cochran Q statistic did
217 not reveal heterogeneity among our genetic instruments, and the MR-Egger intercept

218 test also indicated no presence of pleiotropic effects except those for basophil count.
219 Our MR study was performed with strong instrumental variables and adequate statistical
220 power, and we have conducted extensive sensitivity analyses. Still, we emphasize that
221 our results should be interpreted with caution and future studies are needed to elucidate
222 the mechanistic roles of white blood cell traits in severe COVID-19.

223 **Conclusions**

224 Our results suggest that lower white blood cell count, lower myeloid white blood cell
225 count, lower granulocyte count, and higher eosinophil percentage of white blood cells
226 are causally associated with an increased risk of severe COVID-19.

227 **List of abbreviations**

228 COVID-19: coronavirus disease 2019

229 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

230 MR: Mendelian randomization

231 GWAS: genome-wide association studies

232 SNPs: single nucleotide polymorphisms

233 LD: linkage disequilibrium

234 HGI: Host Genetics Initiative

235 IEU: Integrative Epidemiology Unit

236 IVW: inverse variance-weighted

237 WM: weighted median

238 MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier

239 **Declarations**

240 **Ethics approval and consent to participate**

241 Ethical approval from the North West Multi-Centre Research Ethics Committee and
242 written informed consent from all participants were obtained.

243

244 **Consent for publication**

245 Not applicable.

246

247 **Availability of data and materials**

248 All data generated or analyzed during this study are included in this published article
249 and this supplementary information files.

250

251 **Competing interests**

252 The authors declare that they have no competing interests.

253

254 **Funding**

255 KY is supported by the University of Georgia Research Foundation. Funding sources
256 had no involvement in the conception, design, analysis, or presentation of this work.

257

258 **Authors' contributions**

259 YS, JZ, and KY conceived the study. YS performed data analysis and prepared
260 visualizations. YS, JZ, and KY interpreted the results. YS and KY wrote the first draft of

261 the manuscript. All authors critically read, revised, and approved the final version of the
262 manuscript.

263

264 **Acknowledgments**

265 We would like to express our gratitude to all other Ye lab members for stimulating
266 discussions.

267

268 **ReferencesUncategorized References**

- 269 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X *et al*:
270 **Clinical course and risk factors for mortality of adult inpatients with COVID-19 in**
271 **Wuhan, China: a retrospective cohort study.** *Lancet* 2020, **395**(10229):1054-1062.
- 272 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X *et al*:
273 **Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.**
274 *Lancet* 2020, **395**(10223):497-506.
- 275 3. Wenham C, Smith J, Morgan R, Gender, Group C-W: **COVID-19: the gendered**
276 **impacts of the outbreak.** *Lancet* 2020, **395**(10227):846-848.
- 277 4. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM,
278 Madhur MS, Tomaszewski M, Maffia P, D'Acquisto F *et al*: **COVID-19 and the**
279 **cardiovascular system: implications for risk assessment, diagnosis, and**
280 **treatment options.** *Cardiovasc Res* 2020, **116**(10):1666-1687.
- 281 5. Teng Y, Xu J, Zhang Y, Liu Z, Zhang S: **Mendelian randomization in COVID-19:**
282 **Applications for cardiovascular comorbidities and beyond.** *EBioMedicine* 2020,
283 **57**:102847.
- 284 6. Wu Z, McGoogan JM: **Characteristics of and Important Lessons From the**
285 **Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of**
286 **72314 Cases From the Chinese Center for Disease Control and Prevention.** *JAMA*
287 2020.
- 288 7. Rao S, Lau A, So HC: **Exploring Diseases/Traits and Blood Proteins**
289 **Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A**
290 **Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-**
291 **Related Traits.** *Diabetes Care* 2020, **43**(7):1416-1426.
- 292 8. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere
293 T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M *et al*:
294 **Presence of Genetic Variants Among Young Men With Severe COVID-19.** *JAMA*
295 2020.
- 296 9. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P,
297 Fernandez J, Prati D, Baselli G, Asselta R *et al*: **Genomewide Association Study of**
298 **Severe Covid-19 with Respiratory Failure.** *N Engl J Med* 2020.
- 299 10. Initiative C-HG: **The COVID-19 Host Genetics Initiative, a global initiative to**
300 **elucidate the role of host genetic factors in susceptibility and severity of the**
301 **SARS-CoV-2 virus pandemic.** *Eur J Hum Genet* 2020, **28**(6):715-718.
- 302 11. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q *et al*:
303 **Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-**
304 **19 in Wuhan, China.** *JAMA Cardiol* 2020, **5**(7):802-810.
- 305 12. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W
306 *et al*: **Dysregulation of Immune Response in Patients With Coronavirus 2019**
307 **(COVID-19) in Wuhan, China.** *Clin Infect Dis* 2020, **71**(15):762-768.
- 308 13. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman
309 AR, Agyekum RS, Mathew D, Baxter AE, Vella LA *et al*: **Comprehensive mapping of**
310 **immune perturbations associated with severe COVID-19.** *Sci Immunol* 2020, **5**(49).
- 311 14. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R *et al*:
312 **Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019**
313 **coronavirus disease in the early stage.** *J Transl Med* 2020, **18**(1):206.

- 314 15. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M: **The role of peripheral blood**
315 **eosinophil counts in COVID-19 patients.** *Allergy* 2020.
- 316 16. Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH,
317 Li CH *et al*: **Clinical characteristics of novel coronavirus cases in tertiary hospitals**
318 **in Hubei Province.** *Chin Med J (Engl)* 2020, **133**(9):1025-1031.
- 319 17. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN,
320 Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA: **Hematological findings**
321 **and complications of COVID-19.** *Am J Hematol* 2020, **95**(7):834-847.
- 322 18. Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, Welsh P,
323 Maffia P, Erdmann J, Tomaszewski M *et al*: **White Blood Cells and Blood Pressure:**
324 **A Mendelian Randomization Study.** *Circulation* 2020, **141**(16):1307-1317.
- 325 19. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S *et al*: **Viral**
326 **and host factors related to the clinical outcome of COVID-19.** *Nature* 2020,
327 **583**(7816):437-440.
- 328 20. Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, Zeng S, Ding X, Nie H: **Clinical**
329 **features in 52 patients with COVID-19 who have increased leukocyte count: a**
330 **retrospective analysis.** *Eur J Clin Microbiol Infect Dis* 2020.
- 331 21. Davies NM, Holmes MV, Davey Smith G: **Reading Mendelian randomisation**
332 **studies: a guide, glossary, and checklist for clinicians.** *BMJ* 2018, **362**:k601.
- 333 22. Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F,
334 Holmes M, Minelli C, Relton C *et al*: **Guidelines for performing Mendelian**
335 **randomization investigations [version 2; peer review: 1 approved, 1 approved**
336 **with reservations].** *Wellcome Open Research* 2020, **4**(186).
- 337 23. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C,
338 Burgess S, Bowden J, Langdon R *et al*: **The MR-Base platform supports systematic**
339 **causal inference across the human phenome.** *Elife* 2018, **7**.
- 340 24. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H,
341 Riveros-Mckay F, Kostadima MA *et al*: **The Allelic Landscape of Human Blood Cell**
342 **Trait Variation and Links to Common Complex Disease.** *Cell* 2016, **167**(5):1415-
343 1429 e1419.
- 344 25. Burgess S, Butterworth A, Thompson SG: **Mendelian randomization analysis**
345 **with multiple genetic variants using summarized data.** *Genet Epidemiol* 2013,
346 **37**(7):658-665.
- 347 26. Bowden J, Davey Smith G, Burgess S: **Mendelian randomization with invalid**
348 **instruments: effect estimation and bias detection through Egger regression.** *Int J*
349 *Epidemiol* 2015, **44**(2):512-525.
- 350 27. Bowden J, Davey Smith G, Haycock PC, Burgess S: **Consistent Estimation in**
351 **Mendelian Randomization with Some Invalid Instruments Using a Weighted**
352 **Median Estimator.** *Genet Epidemiol* 2016, **40**(4):304-314.
- 353 28. Verbanck M, Chen CY, Neale B, Do R: **Detection of widespread horizontal**
354 **pleiotropy in causal relationships inferred from Mendelian randomization between**
355 **complex traits and diseases.** *Nat Genet* 2018, **50**(5):693-698.
- 356 29. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD:
357 **Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.**
358 *Allergy* 2020, **75**(7):1730-1741.

- 359 30. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X, Wei H:
360 **Pathogenic T cells and inflammatory monocytes incite inflammatory storm in**
361 **severe COVID-19 patients.** *Natl Sci Rev* 2020:nwaa041.
- 362 31. Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, Tang Y, Zhang N, Zan T,
363 Gao L *et al*: **The underlying changes and predicting role of peripheral blood**
364 **inflammatory cells in severe COVID-19 patients: A sentinel?** *Clin Chim Acta* 2020,
365 **508**:122-129.
- 366 32. Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L *et al*:
367 **Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients**
368 **in fever clinic: A retrospective case-control study.** *EClinicalMedicine* 2020,
369 **23**:100375.
- 370 33. Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A,
371 Ostro R, Banovcin P: **Immune Parameters and COVID-19 Infection - Associations**
372 **With Clinical Severity and Disease Prognosis.** *Front Cell Infect Microbiol* 2020,
373 **10**:364.
- 374 34. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC,
375 O'Mahony L, Gao Y, Nadeau K, Akdis CA: **Immune response to SARS-CoV-2 and**
376 **mechanisms of immunopathological changes in COVID-19.** *Allergy* 2020,
377 **75(7)**:1564-1581.
- 378 35. Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, Ge L, Hu Q: **Correlation**
379 **analysis between disease severity and clinical and biochemical characteristics of**
380 **143 cases of COVID-19 in Wuhan, China: a descriptive study.** *BMC Infect Dis* 2020,
381 **20(1)**:519.
- 382 36. Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, Liu W, Tu S, Zhang M,
383 Wang Q *et al*: **Correlation Analysis Between Disease Severity and Inflammation-**
384 **related Parameters in Patients with COVID-19 Pneumonia.**
385 2020:2020.2002.2025.20025643.
- 386 37. Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH: **Eosinopenia**
387 **and COVID-19.** *J Am Osteopath Assoc* 2020.
- 388 38. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu
389 JG, Chen L *et al*: **Epidemiologic and clinical characteristics of 91 hospitalized**
390 **patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case**
391 **series.** *QJM* 2020, **113(7)**:474-481.
- 392 39. Lippi G, Henry BM: **Eosinophil count in severe coronavirus disease 2019.**
393 *QJM* 2020, **113(7)**:511-512.
- 394 40. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J: **Patients of**
395 **COVID-19 may benefit from sustained Lopinavir-combined regimen and the**
396 **increase of Eosinophil may predict the outcome of COVID-19 progression.** *Int J*
397 *Infect Dis* 2020, **95**:183-191.
- 398 41. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, Chen C, Pan Y, Hu X: **Abnormalities**
399 **of peripheral blood system in patients with COVID-19 in Wenzhou, China.** *Clin*
400 *Chim Acta* 2020, **507**:174-180.
- 401 42. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle
402 L, Moreira A, Park MD *et al*: **Immunology of COVID-19: Current State of the Science.**
403 *Immunity* 2020, **52(6)**:910-941.

- 404 43. Rothan HA, Byrareddy SN: **The epidemiology and pathogenesis of**
405 **coronavirus disease (COVID-19) outbreak.** *J Autoimmun* 2020, **109**:102433.
- 406 44. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong
407 Y *et al*: **Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel**
408 **Coronavirus-Infected Pneumonia in Wuhan, China.** *JAMA* 2020, **323**(11):1061-1069.
- 409 45. Ding Q, Lu P, Fan Y, Xia Y, Liu M: **The clinical characteristics of pneumonia**
410 **patients coinfectd with 2019 novel coronavirus and influenza virus in Wuhan,**
411 **China.** *J Med Virol* 2020.
- 412 46. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui
413 DSC *et al*: **Clinical Characteristics of Coronavirus Disease 2019 in China.** *N Engl J*
414 *Med* 2020, **382**(18):1708-1720.
- 415 47. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D: **Early Clinical and CT**
416 **Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia.** *AJR Am J*
417 *Roentgenol* 2020, **215**(2):338-343.
- 418 48. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J *et*
419 *al*: **Clinical characteristics and imaging manifestations of the 2019 novel**
420 **coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang,**
421 **China.** *J Infect* 2020, **80**(4):388-393.
- 422 49. Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, Lin MG, Mu XD:
423 **[Clinical features of 2019 novel coronavirus pneumonia in the early stage from a**
424 **fever clinic in Beijing].** *Zhonghua Jie He He Hu Xi Za Zhi* 2020, **43**(0):E013.
- 425 50. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX,
426 Huang K, Zeng QT: **[Clinical characteristics and outcomes of 112 cardiovascular**
427 **disease patients infected by 2019-nCoV].** *Zhonghua Xin Xue Guan Bing Za Zhi* 2020,
428 **48**(6):450-455.
- 429 51. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong
430 Y *et al*: **Clinical features and treatment of COVID-19 patients in northeast**
431 **Chongqing.** *J Med Virol* 2020, **92**(7):797-806.
- 432 52. Sattar N, Preiss D: **Reverse Causality in Cardiovascular Epidemiological**
433 **Research: More Common Than Imagined?** *Circulation* 2017, **135**(24):2369-2372.
- 434 53. Zhou J, Sun Y, Huang W, Ye K: **Altered blood cell traits underlie a major**
435 **genetic locus of severe COVID-19.** 2020:2020.2009.2009.20191700.
- 436

437 **Tables**

438 **Table 1.** Causal associations between white blood cell traits and severe COVID-19
439 based on random-effects IVW MR estimation.

440

441 **Figure legends**

442 **Figure 1.** Odds ratios for associations between genetically predicted risk factors and
443 severe COVID-19. Analyses were done with the inverse variance-weighted (IVW)
444 method with a multiplicative random-effects model. Effect estimates express the change
445 in odds ratio (OR) per standard deviation (SD) increment in white blood cell traits, error
446 bars indicate 95% confidence intervals. WBC#: White blood cell count; EO#: Eosinophil
447 count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count;
448 LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#:
449 Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#:
450 Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells;
451 BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of
452 white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%:
453 Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte
454 percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of
455 granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN:
456 Neutrophil percentage of granulocytes.

457 **Supplemental Data**

458 Supplementary Table 1. Summary of GWAS information for white blood cell
459 phenotypes

460 Supplementary Table 2. 167 SNPs used IVs in MR analyses testing effect of white
461 blood cell count on severe COVID-19 risk.

462 Supplementary Table 3. 169 SNPs used IVs in MR analyses testing effect of eosinophil
463 count on severe COVID-19 risk.

464 Supplementary Table 4. 79 SNPs used IVs in MR analyses testing effect of basophil
465 count on severe COVID-19 risk.

466 Supplementary Table 5. 140 SNPs used IVs in MR analyses testing effect of neutrophil
467 count on severe COVID-19 risk.

468 Supplementary Table 6. 185 SNPs used IVs in MR analyses testing effect of monocyte
469 count on severe COVID-19 risk.

470 Supplementary Table 7. 160 SNPs used IVs in MR analyses testing effect of
471 lymphocyte count on severe COVID-19 risk.

472 Supplementary Table 8. 146 SNPs used IVs in MR analyses testing effect of myeloid
473 white blood cell count on severe COVID-19 risk.

474 Supplementary Table 9. 144 SNPs used IVs in MR analyses testing effect of
475 granulocyte count on severe COVID-19 risk.

476 Supplementary Table 10. 139 SNPs used IVs in MR analyses testing effect of sum
477 neutrophil eosinophil counts on severe COVID-19 risk.

478 Supplementary Table 11. 142 SNPs used IVs in MR analyses testing effect of sum
479 basophil neutrophil counts on severe COVID-19 risk.

480 Supplementary Table 12. 158 SNPs used IVs in MR analyses testing effect of
481 eosinophil percentage of white blood cells on severe COVID-19 risk.

482 Supplementary Table 13. 63 SNPs used IVs in MR analyses testing effect of basophil
483 percentage of white blood cells on severe COVID-19 risk.

484 Supplementary Table 14. 135 SNPs used IVs in MR analyses testing effect of neutrophil
485 percentage of white blood cells on severe COVID-19 risk.

486 Supplementary Table 15. 191 SNPs used IVs in MR analyses testing effect of monocyte
487 percentage of white blood cells on severe COVID-19 risk.

488 Supplementary Table 16. 135 SNPs used IVs in MR analyses testing effect of
489 lymphocyte percentage of white blood cells on severe COVID-19 risk.

490 Supplementary Table 17. 168 SNPs used IVs in MR analyses testing effect of
491 granulocyte percentage of myeloid white blood cells on severe COVID-19 risk.

492 Supplementary Table 18. 150 SNPs used IVs in MR analyses testing effect of
493 eosinophil percentage of granulocytes on severe COVID-19 risk.

494 Supplementary Table 19. 59 SNPs used IVs in MR analyses testing effect of basophil
495 percentage of granulocytes on severe COVID-19 risk.

496 Supplementary Table 20. 141 SNPs used IVs in MR analyses testing effect of neutrophil
497 percentage of granulocytes on severe COVID-19 risk.

498 Supplementary Table 21. MR estimates from each method of assessing the causal
499 effects of white blood cells on severe COVID-19 risk.

500 Supplementary Figure 1. Scatter plots of the genetic associations of white blood cell
501 count (A), or myeloid white blood cell count (B), or granulocyte count (C), or basophil
502 count (D) or eosinophil percentage in white blood cells (E) associated SNPs against the

503 genetic associations of severe COVID-19. The slopes of each line represent the causal
504 association using different MR methods. The light blue line represents the random-
505 effects inverse variance-weighted estimate, the dark blue line represents the MR-Egger
506 estimate, and the green line represents the weighted median estimate.

Tables

Table 1. Causal associations between white blood cell traits and severe COVID-19 based on random-effects IVW MR estimation.

Exposure	Number of SNPs	Odds ratio	95% CI	<i>P</i> -value	Heterogeneity <i>P</i> -value	MR-Egger intercept test <i>P</i> -value
WBC#	167	0.84	0.72, 0.98	0.031	0.847	0.406
EO#	169	1.15	0.98, 1.36	0.086	0.188	0.485
BASO#	79	0.75	0.58, 0.96	0.023	0.570	0.037
NEUT#	140	0.87	0.74, 1.04	0.119	0.804	0.631
MONO#	185	0.93	0.83, 1.06	0.285	0.592	0.714
LYMPH#	160	0.94	0.79, 1.12	0.486	0.145	0.875
MYELOID#	146	0.81	0.70, 0.94	0.0070	0.974	0.901
GRAN#	144	0.84	0.71, 0.99	0.040	0.868	0.378
(NEUT+EO)#	139	0.85	0.73, 1.00	0.051	0.941	0.470
(BASO+NEUT)#	142	0.87	0.74, 1.03	0.098	0.873	0.408
EO%	158	1.22	1.03, 1.45	0.023	0.209	0.808
BASO%	63	0.82	0.64, 1.05	0.122	0.821	0.063

NEUT%	135	1.15	0.94, 1.40	0.169	0.550	0.105
MONO%	191	0.95	0.84, 1.08	0.457	0.656	0.388
LYMPH%	135	1.06	0.87, 1.30	0.548	0.380	0.859
GRAN%MYELOID	168	1.07	0.94, 1.22	0.325	0.894	0.746
EO%GRAN	150	1.18	1.00, 1.39	0.053	0.647	0.866
BASO%GRAN	59	0.84	0.65, 1.09	0.182	0.768	0.117
NEUT%GRAN	141	0.85	0.71, 1.02	0.083	0.327	0.861

WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

White Blood Cell Traits

